| Name | Title | Contact Details |
|---|
Founded in Los Angeles in 2007, Cinesamples has grown to become an industry leader in the development of top virtual instruments and sample libraries. We are passionate about the sampling process, and you can hear our products in many films, tv shows, and video games.
EDGAR COUNTY BANK IS NOW PROSPECT BANK Edgar County Bank opened its doors in 1873 with a single mission: To help people achieve the American Dream. That mission is as true today as it was 144 years ago. Over time, weve grown alongside the Central Illinois community—and thanks to your support, weve expanded beyond Edgar County. Thats why, effective immediately, Edgar County Bank is now Prospect Bank: a name that reflects who we are today, and our plans for the future. We believe in the people of Central Illinois. As Prospect Bank, were not going anywhere. Were going everywhere—and were excited to show you what we can do for you. If you have any questions about our name change or anything related to Prospect Bank, dont hesitate to contact us. https://www.bankprospect.com/
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.